An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited announced a change in the interests of substantial holders due to the dilution of shares from recent placements. Despite the decrease in voting power, no shares were sold by Velocimetry Consulting Pty Ltd, Andreas Fouras, or Helen Fouras. This announcement reflects the company’s ongoing strategic adjustments and could influence stakeholder perceptions regarding its market positioning.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced imaging and AI-powered solutions for respiratory care. The company’s patented XV Technology® provides detailed insights into lung function, supporting early and precise diagnoses of respiratory diseases. Their solutions, including the FDA-cleared XV Lung Ventilation Analysis Software, integrate into existing hospital systems via a SaaS model. In December 2023, 4DMedical expanded its capabilities by acquiring Imbio, enhancing its AI-driven platforms for chronic lung and cardiothoracic diseases.
YTD Price Performance: -13.54%
Average Trading Volume: 936,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$171.9M
See more data about 4DX stock on TipRanks’ Stock Analysis page.